Sector › Medicine

Press Releases

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

Apr 16, 2024 17:35 HKT/SGT

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Apr 16, 2024 17:04 HKT/SGT

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Apr 10, 2024 12:36 HKT/SGT

Chiron AS in Trondheim, Norway, Has Developed The World's First Commercial Microplastic Reference Materials

Apr 09, 2024 22:30 HKT/SGT

BYND Cannasoft Announces RSU Grant

Apr 08, 2024 20:00 HKT/SGT

NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines

Apr 08, 2024 12:45 HKT/SGT

The $7 Billion CBD Market in 2023 is Focused on Significant Growth in Personal Care

Apr 05, 2024 21:00 HKT/SGT

World Hepatitis Summit 2024 Convenes in Lisbon

Apr 04, 2024 19:00 HKT/SGT

A $45 Billion Dollars Market is in the Crosshairs of BYND Cannasoft with a New Series of Concept Smart Fem-Tech Devices

Apr 03, 2024 21:30 HKT/SGT

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Apr 03, 2024 20:00 HKT/SGT

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

Apr 03, 2024 15:24 HKT/SGT

沛嘉醫療(09996.HK)因金融資產評估而停牌

Apr 03, 2024 10:23 HKT/SGT

沛嘉医疗(09996.HK)因金融资产评估停牌

Apr 03, 2024 10:19 HKT/SGT

Israeli Technology Company BYND Cannasoft Enterprises Inc. Announces Financial Results For The Year Ended December 31, 2023

Apr 03, 2024 10:00 HKT/SGT

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

Apr 01, 2024 21:30 JST

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

Apr 01, 2024 20:30 HKT/SGT

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Apr 01, 2024 08:39 HKT/SGT

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

Mar 29, 2024 14:51 HKT/SGT

Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

Mar 29, 2024 14:19 HKT/SGT

Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024

Mar 29, 2024 13:32 HKT/SGT